by Giulia Iacono, Christina Begka, Bailey Cardwell, Carmel Daunt, Roxanne Chatzis, Celine Pattaroni, Alana Butler, Matthew Macowan, Bronwyn Levvey, Gregory I. Snell, Glen P.
Westall, Benjamin J. Marsland Background Long-term survival of lung transplant recipients remains limited by chronic lung allograft dysfunction (CLAD).
CLAD is only diagnosed following a persistent and substantial decline in lung function, after which irreversible damage to the lungs has occurred, limiting opportunities to effectively intervene at an early stage. There is a critical need for earlier detection prior to its clinical manifestation.
The immunological drivers of CLAD remain unclear, limiting the development of predictive biomarkers and new therapies. Methods and findings In this hypothesis-generating, prospective cohort study, we profiled the microbial, metabolic, lipidomic, and gene expression dynamics of longitudinally collected broncho-alveolar lavages (BALs) from 56 CLAD-free lung transplant recipients up to 30 months post-transplant, and compared BALs from 13 CLAD-free patients to BALs from 13 patients who developed CLAD.
PLOS Medicine published a clinical update in Research Highlights on 23 Jun 2026.
The item focuses on Multi-omics biomarkers of endothelial dysregulation preceding chronic lung allograft dysfunction: A prospective cohort study.
Review the original article for the full source wording and details.